Loading...

HSCS HEARTSCIENCES INC US FDA Inspections 8-K Filing

HRTS

HSCS

HEARTSCIENCES INC

(HSCS)

2025 8-K

Show Summary

Show Summary

Pre-Market Approval

Equity Offerings

Equity Offerings

Voluntary Delisting

Nasdaq Compliance Issue

Financial Results

Stock Options Award

Public Offering Withdrawal

Financial Results

Annual Meeting Results

Financial Results

Note Purchase Agreement

Loan Agreement Update

Results of Operations and F...

Compliance Regained with Na...

Amendment to Form 8-K/A

Reverse Stock Split

Earnings Reports

Annual Meeting Results

Annual Meeting of Shareholders

Earnings Reports

Agreement with Mount Sinai

Compliance with Nasdaq List...

Compliance with Nasdaq List...

Loan Agreement, Warrant Iss...

Equity Distribution Agreement

Equity Distribution Agreement

License Agreements and Secu...

Earnings Report

Patent Allowance Announcement

Financial Statements

Stock Options Awarded

Press Release and Equity In...

Purchase Agreement and Regi...

Equity Issuance

Amendment to Warrants

Amendment to Loan Agreement

Equity Investment

Resignation and Appointment...

External Links:

On June 4, 2025, HeartSciences Inc. announced it received a Breakthrough Device designation from the FDA for its Aortic Stenosis ECG algorithm, which could expedite its development and market access.

AI Assistant

HEARTSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.